Tryg A/S
17.3.2025 12:00:00 CET | Globenewswire | Press release
Transactions in connection with share buyback programme
Transactions in connection with share buyback programme
Tryg - Transactions in connection with share buyback programme
On 04 December 2024, Tryg A/S (“Tryg”) announced that the Board of Directors had decided to initiate a share buyback programme of up to DKK 2.0 billion. The share buyback programme is executed in accordance with EU Market Abuse Regulation, EU Regulation no. 596/2014 of 16 April 2014 and the provisions of Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the “Safe Harbour Regulation”). The share buyback programme will end no later than 30 June 2025.
Transactions made under the share buyback programme will be announced through Nasdaq Copenhagen on a weekly basis.
The following transactions have been executed in the period 10 March 2025 to 14 March 2025:
| Number of shares | Avg. purchase price, DKK | Transaction value, DKK | |
| 10 March 2025 | 80,000 | 156.58 | 12,526,400 |
| 11 March 2025 | 60,000 | 158.61 | 9,516,600 |
| 12 March 2025 | 70,000 | 157.44 | 11,020,800 |
| 13 March 2025 | 60,000 | 159.57 | 9,574,200 |
| 14 March 2025 | 60,000 | 160.02 | 9,601,200 |
| Accumulated for the period | 330,000 | 52,239,200 | |
| Accumulated under the programme | 8,115,787 | 1,232,546,904 |
Detailed information on all transactions under the share buyback programme during the period is included in the attached appendix.
Following the above transactions, Tryg owns a total of 8,621,572 treasury shares corresponding to 1.399% of the total share capital.
Attachment
Documents
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
King Faisal Specialist Hospital & Research Centre13.3.2026 22:15:53 CET | Press release
KFSH Leads Globally in Paired Kidney Transplants Performed at a Single Center in 2025
SCOR13.3.2026 18:59:39 CET | Press release
SCOR SE announces the availability of its 2025 Universal Registration Document
Novartis Pharma AG13.3.2026 18:35:19 CET | Press release
Novartis Cosentyx® receives FDA approval for pediatric patients aged 12+ with moderate to severe hidradenitis suppurativa
Luotea Oyj13.3.2026 18:30:00 CET | Press release
The Board of Directors of Luotea Oyj decided on updates to the company's share-based incentive plan for 2023-2027 and on the launch of a new share-based incentive plan for the years 2026-2030
Ilkka Oyj13.3.2026 18:00:00 CET | Press release
Ilkka Oyj: Acquisition of own shares on 13 March 2026
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom